Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. More Details
Excellent balance sheet with proven track record.
Share Price & News
How has Medpace Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MEDP has not had significant price volatility in the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: MEDP exceeded the US Life Sciences industry which returned 48.6% over the past year.
Return vs Market: MEDP exceeded the US Market which returned 18.3% over the past year.
Price Volatility Vs. Market
How volatile is Medpace Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIs It Too Late To Consider Buying Medpace Holdings, Inc. (NASDAQ:MEDP)?
3 weeks ago | Simply Wall StEstimating The Intrinsic Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
1 month ago | Simply Wall StMedpace Holdings's (NASDAQ:MEDP) Earnings Are Growing But Is There More To The Story?
Is Medpace Holdings undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MEDP ($116.54) is trading above our estimate of fair value ($98.38)
Significantly Below Fair Value: MEDP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MEDP is good value based on its PE Ratio (39.2x) compared to the US Life Sciences industry average (45.7x).
PE vs Market: MEDP is poor value based on its PE Ratio (39.2x) compared to the US market (19.2x).
Price to Earnings Growth Ratio
PEG Ratio: MEDP is poor value based on its PEG Ratio (2.5x)
Price to Book Ratio
PB vs Industry: MEDP is good value based on its PB Ratio (5.6x) compared to the US Life Sciences industry average (7.1x).
How is Medpace Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MEDP's forecast earnings growth (15.6% per year) is above the savings rate (2.2%).
Earnings vs Market: MEDP's earnings (15.6% per year) are forecast to grow slower than the US market (22.1% per year).
High Growth Earnings: MEDP's earnings are forecast to grow, but not significantly.
Revenue vs Market: MEDP's revenue (15.1% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: MEDP's revenue (15.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MEDP's Return on Equity is forecast to be low in 3 years time (19.6%).
How has Medpace Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MEDP has high quality earnings.
Growing Profit Margin: MEDP's current net profit margins (12.1%) are higher than last year (11.2%).
Past Earnings Growth Analysis
Earnings Trend: MEDP has become profitable over the past 5 years, growing earnings by 56.7% per year.
Accelerating Growth: MEDP's earnings growth over the past year (20.4%) is below its 5-year average (56.7% per year).
Earnings vs Industry: MEDP earnings growth over the past year (20.4%) exceeded the Life Sciences industry 17%.
Return on Equity
High ROE: MEDP's Return on Equity (14.5%) is considered low.
How is Medpace Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: MEDP's short term assets ($319.1M) do not cover its short term liabilities ($338.0M).
Long Term Liabilities: MEDP's short term assets ($319.1M) exceed its long term liabilities ($146.1M).
Debt to Equity History and Analysis
Debt Level: MEDP is debt free.
Reducing Debt: MEDP has no debt compared to 5 years ago when its debt to equity ratio was 106.8%.
Debt Coverage: MEDP has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MEDP has no debt, therefore coverage of interest payments is not a concern.
What is Medpace Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MEDP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MEDP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MEDP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MEDP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MEDP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
August Troendle (64 yo)
Dr. August James Troendle, M.D. has been the Chairman, Chief Executive Officer and President at Medpace Holdings, Inc. since July 1992. Dr. Troendle founded Medpace Holdings, Inc. in July 1992. He founded ...
CEO Compensation Analysis
Compensation vs Market: August's total compensation ($USD7.71M) is above average for companies of similar size in the US market ($USD5.61M).
Compensation vs Earnings: August's compensation has increased by more than 20% in the past year.
|CFO & COO of Laboratory Operations||9.58yrs||US$1.88m||0.018% |
|Executive Vice President of Operations||3.75yrs||US$2.43m||0.17% |
|Chief Compliance Officer||0.67yr||US$1.25m||0.0095% |
|Vice President of Business Development & Marketing||no data||no data||no data|
|Senior Vice President of Biometrics||no data||no data||no data|
|Senior Vice President of Medical Department||no data||no data||no data|
|Senior Vice President of Commercial Operations & Clinical Pharmacology Unit||no data||no data||no data|
|Executive Director of Finance||no data||no data||no data|
Experienced Management: MEDP's management team is seasoned and experienced (6.7 years average tenure).
|Lead Independent Director||2yrs||US$142.60k||0.0043% |
|Independent Director||2.17yrs||US$135.10k||0% |
|Independent Director||1yr||US$60.29k||0% |
|Independent Director||4.25yrs||US$144.99k||0% |
|Independent Director||4.25yrs||US$149.99k||0% |
|Independent Director||1.42yrs||US$114.94k||0% |
Experienced Board: MEDP's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MEDP insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Medpace Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Medpace Holdings, Inc.
- Ticker: MEDP
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.103b
- Shares outstanding: 35.21m
- Website: https://www.medpace.com
Number of Employees
- Medpace Holdings, Inc.
- 5375 Medpace Way
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|01P||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 2016|
|MEDP||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Aug 2016|
|MEDP *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Aug 2016|
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industrie ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/25 00:36|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.